1h Free Analyst Time
Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) pipeline Target constitutes close to 15 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes. The latest report Heparanase - Drugs In Development, 2022, outlays comprehensive information on the Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.Speak directly to the analyst to clarify any post sales queries you may have.
Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) - Heparanase is an endoglycosidase which cleaves heparan sulfate (HS) and hence participates in degradation and remodeling of the extracellular matrix (ECM). Heparanase is preferentially expressed in human tumors and its over-expression in tumor cells. The enzyme also releases angiogenic factors from the ECM and thereby induces an angiogenic response. Heparanase exhibits also non-enzymatic activities, independent of its involvement in ECM degradation. Among these, are the enhancement of Akt signaling, stimulation of PI3K- and p38-dependent endothelial cell migration, and up regulation of VEGF, all contributing to its potent pro-angiogenic activity. Inhibiting the enzyme is beneficial in treatment of cancer. The molecules developed by companies in Phase II, Preclinical and Discovery stages are 2, 4 and 8 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Infectious Disease, Ophthalmology, Hematological Disorders and Immunology which include indications Coronavirus Disease 2019 (COVID-19), Melanoma, Pancreatic Cancer, Retinopathy, Blood Coagulation, Breast Cancer, Dengue Fever, Dry (Atrophic) Macular Degeneration, Head And Neck Cancer, Inflammation, Metastatic Adenocarcinoma of The Pancreas, Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Non-Small Cell Lung Cancer, Refractory Multiple Myeloma, Solid Tumor, Triple-Negative Breast Cancer (TNBC), Unspecified Cancer and Wet (Neovascular/Exudative) Macular Degeneration.
Furthermore, this report also reviews key players involved in Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166)
- The report reviews Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) targeted therapeutics and enlists all their major and minor projects
- The report assesses Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
- Introduction
- REPORT COVERAGE
- Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) - Overview
- Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) - Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) - Companies Involved in Therapeutics Development
- B-Side Pharma Ltd
- Beta Therapeutics Pty Ltd
- CarboMimetics
- HepaRx Ltd
- Johnson & Johnson
- Leadiant Biosciences Inc
- Shenzhen Hepalink Pharmaceutical Group Co Ltd
- Zucero Therapeutics Ltd
- Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) - Drug Profiles
- BT-2180 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- CM-30119 - Drug Profile
- Product Description
- Mechanism Of Action
- H-1710 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- JVB-001 - Drug Profile
- Product Description
- Mechanism Of Action
- JVB-002 - Drug Profile
- Product Description
- Mechanism Of Action
- JVB-003 - Drug Profile
- Product Description
- Mechanism Of Action
- JVB-14 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- necuparanib - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- pixatimod - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Polysaccharides to Inhibit Heparanase for Unspecified Cancer - Drug Profile
- Product Description
- Mechanism Of Action
- roneparstat - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecule to Inhibit Heparanase for Oncology - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules to Inhibit Heparanase for Inflammatory Diseases and Oncology - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecules to Inhibit Heparanase for Type 1 and Type 2 Diabetes and Age Related Macular Degeneration - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Synthetic Peptide to Inhibit HPSE and VEGF for Oncology - Drug Profile
- Product Description
- Mechanism Of Action
- Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) - Dormant Products
- Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) - Discontinued Products
- Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) - Product Development Milestones
- Featured News & Press Releases
- Aug 04, 2016: Momenta Discontinues Further Accrual of its Phase 2 Trial of Necuparanib in Patients with Pancreatic Cancer Following Planned Interim Futility Analysis
- Jun 04, 2016: Momenta Pharmaceuticals Announces Presentation of Final Data from Phase 1 Trial of Necuparanib in Patients with Pancreatic Cancer at ASCO
- May 19, 2016: Momenta Pharmaceuticals Announces Data Presentation on Necuparanib at the 2016 ASCO Annual Meeting
- Dec 21, 2015: Momenta Resumes Patient Enrollment in the Necuparanib (MOM-M402-103) Phase 2 Study
- Nov 13, 2015: Momenta Announces Temporary Pause of Patient Enrollment in the Necuparanib (MOM-M402-103) Phase 2 Study
- Jun 01, 2015: Momenta Pharmaceuticals to Present New Data From Phase 1 Trial of Necuparanib in Patients With Pancreatic Cancer
- May 18, 2015: Momenta Pharmaceuticals Announces Data Presentation on Necuparanib (M402) at the 2015 ASCO Annual Meeting
- Dec 01, 2014: Momenta Pharmaceuticals' Necuparanib Receives Fast Track Designation From the FDA for the Treatment of Patients With Metastatic Pancreatic Cancer
- Oct 09, 2014: Momenta Pharmaceuticals Announces Top-Line Part A Results From Phase 1/2 Trial of Necuparanib in Patients With Pancreatic Cancer
- Oct 09, 2014: Momenta Pharmaceuticals Announces Top-Line Part A Results From Phase 1/2 Trial of Necuparanib in Patients With Pancreatic Cancer
- Jul 21, 2014: European Patent Office Intention to Grant ‘Sulfated Oligosaccharide Derivatives’ Patent
- Jun 05, 2014: Momenta Pharmaceuticals Receives Orphan Drug Designation for Necuparanib (Formerly M402) in Pancreatic Cancer
- Oct 29, 2013: PG545 Phase 1 Cancer Trial Update
- Jul 09, 2013: PG545 Pre-Clinical Data in Experimental Pancreatic Cancer Models Published in Molecular Cancer Therapeutics
- May 13, 2013: Sigma-Tau announces Phase I study with new anti-cancer heparanase inhibitor SST0001
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
List of Tables
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Indication, 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Number of Products under Investigation by Universities/Institutes, 2022
- Products under Investigation by Universities/Institutes, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Pipeline by B-Side Pharma Ltd, 2022
- Pipeline by Beta Therapeutics Pty Ltd, 2022
- Pipeline by CarboMimetics, 2022
- Pipeline by HepaRx Ltd, 2022
- Pipeline by Johnson & Johnson, 2022
- Pipeline by Leadiant Biosciences Inc, 2022
- Pipeline by Shenzhen Hepalink Pharmaceutical Group Co Ltd, 2022
- Pipeline by Zucero Therapeutics Ltd, 2022
- Dormant Products, 2022
- Discontinued Products, 2022
List of Figures
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Top 10 Indications, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- B-Side Pharma Ltd
- Beta Therapeutics Pty Ltd
- CarboMimetics
- HepaRx Ltd
- Johnson & Johnson
- Leadiant Biosciences Inc
- Shenzhen Hepalink Pharmaceutical Group Co Ltd
- Zucero Therapeutics Ltd
